人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识

2020-03-25 中国感染病相关专家组(统称) 中国艾滋病性病.2020,26(3):331-335.

近年来,越来越多的二联简化治疗方案不断涌现,在为临床医生提供更多的治疗选择的同时,也给规范简化治疗带来了挑战。中国性病艾滋病防治协会临床治疗学组制定了《人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法

中文标题:

人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识

发布日期:

2020-03-25

简要介绍:

近年来,越来越多的二联简化治疗方案不断涌现,在为临床医生提供更多的治疗选择的同时,也给规范简化治疗带来了挑战。中国性病艾滋病防治协会临床治疗学组制定了《人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识》。此共识是基于国际上最新的相关临床研究数据、指南以及我国的临床应用实践来进行编写,就不同情况下的二联方案的选择和适用条件做出总结,为临床医护人员提供参考与指导。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5adc01c001895857, title=人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识, enTitle=, guiderFrom=中国艾滋病性病.2020,26(3):331-335., authorId=0, author=, summary=近年来,越来越多的二联简化治疗方案不断涌现,在为临床医生提供更多的治疗选择的同时,也给规范简化治疗带来了挑战。中国性病艾滋病防治协会临床治疗学组制定了《人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法, cover=https://img.medsci.cn/2020426/1587911623910_2020535.jpg, journalId=0, articlesId=null, associationId=858, associationName=中国感染病相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Mar 25 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>近年来,越来越多的二联简化治疗方案不断涌现,在为临床医生提供更多的治疗选择的同时,也给规范简化治疗带来了挑战。中国性病艾滋病防治协会临床治疗学组制定了《人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识》。此共识是基于国际上最新的相关临床研究数据、指南以及我国的临床应用实践来进行编写,就不同情况下的二联方案的选择和适用条件做出总结,为临床医护人员提供参考与指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1837, tagName=抗病毒治疗), TagDto(tagId=22278, tagName=人类免疫缺陷病毒)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1837, guiderKeyword=抗病毒治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2552, appHits=73, showAppHits=8, pcHits=979, showPcHits=2503, likes=1, shares=4, comments=2, approvalStatus=1, publishedTime=Sun Apr 26 23:10:10 CST 2020, publishedTimeString=2020-03-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 26 22:33:46 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 15:15:58 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识.pdf)])
人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=961278, encodeId=f98a9612e898, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fdc5443993, createdName=ms9000000104119158, createdTime=Wed Apr 28 18:44:45 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898790, encodeId=e963898e906c, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 20:00:03 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-04-28 ms9000000104119158

    想看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=961278, encodeId=f98a9612e898, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fdc5443993, createdName=ms9000000104119158, createdTime=Wed Apr 28 18:44:45 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898790, encodeId=e963898e906c, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e95433715, createdName=ms6000001414112870, createdTime=Thu Nov 12 20:00:03 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 ms6000001414112870

    0